How to Safely Stop Flibanserin (Addyi): Discontinuation Protocol

Why Flibanserin Does Not Require a Taper

Unlike benzodiazepines or SSRIs, flibanserin has no documented discontinuation syndrome. The drug's relatively short elimination half-life of approximately 11 hours means plasma concentrations drop below clinically meaningful levels within 48 to 55 hours of the last dose [1]. This pharmacokinetic profile works in favor of a clean stop.

Flibanserin acts on serotonin receptors as a 5-HT1A agonist and 5-HT2A antagonist, with secondary effects on dopamine [2]. That mechanism differs from SSRIs, which increase synaptic serotonin broadly and can produce discontinuation symptoms (dizziness, paresthesia, irritability) when withdrawn abruptly. Flibanserin modulates the balance between excitatory and inhibitory neurotransmitters involved in sexual desire rather than saturating a single receptor system. The 2015 FDA medical review for NDA 022526 noted no signal for rebound or withdrawal across the key trial database [3].

In the BEGONIA trial (N=1,175), participants who completed 24 weeks of treatment discontinued without a taper period, and investigators recorded no cluster of new-onset symptoms attributable to drug cessation [4]. The same pattern held in the DAISY and VIOLET trials. No post-marketing safety signal for withdrawal has appeared in the FDA Adverse Event Reporting System through 2025 [3].

How Flibanserin Works (and Why That Matters for Stopping)

Flibanserin corrects a neurochemical imbalance rather than producing a pharmacological "high." It increases dopamine and norepinephrine activity in the prefrontal cortex while reducing serotonin's inhibitory tone on desire circuits [2]. This is a slow, cumulative effect. Most women do not notice benefit until four to eight weeks of nightly dosing.

That gradual onset mirrors a gradual offset. Because the drug does not create receptor dependence the way opioids or benzodiazepines do, the brain does not "miss" it acutely when it is removed. Dr. Sheryl Kingsberg, a clinical psychologist and researcher involved in flibanserin's development, stated in a 2015 expert panel: "Flibanserin restores balance in neurotransmitter systems rather than creating a new equilibrium that the brain must then readjust from" [5]. The clinical translation is straightforward. Stop the pill, and desire gradually returns to its pre-treatment baseline.

One nuance worth noting: if a woman experienced improved desire on flibanserin and stops, the return of low desire is not withdrawal. It is the re-emergence of the underlying condition, hypoactive sexual desire disorder (HSDD). Distinguishing recurrence from withdrawal matters for clinical decision-making [6].

Step-by-Step Protocol for Stopping Addyi

The process is simpler than most patients expect. Here is the recommended sequence, synthesized from the prescribing information and expert consensus [1][6]:

Step 1: Talk to your prescriber. Before stopping, discuss whether the original indication (HSDD) has been adequately addressed. If desire improved, explore whether behavioral or relationship-based strategies can sustain gains. If the drug did not work after eight weeks of continuous use, the FDA label recommends discontinuation [1].

Step 2: Choose your last dose. Take the final 100 mg tablet at bedtime as usual. There is no need to cut tablets in half or alternate days.

Step 3: Monitor for 7 to 14 days. Track desire levels, mood, and sleep quality. Most women report stable mood and no physical symptoms. Desire typically returns to pre-treatment levels within this window [4].

Step 4: Reassess at 4 weeks. Schedule a follow-up with your prescriber to evaluate whether HSDD symptoms have returned and whether alternative management (psychotherapy, hormonal evaluation, or a different pharmacologic approach) is appropriate [6].

Step 5: Lift alcohol restrictions. While on flibanserin, alcohol increases the risk of severe hypotension and syncope. The REMS program requires prescribers to counsel patients about this interaction [7]. Once the drug has cleared your system (roughly 2 days after the last dose), this restriction no longer applies.

What the Clinical Trial Data Show About Post-Discontinuation Outcomes

Three key Phase III trials enrolled a combined 3,548 premenopausal women with HSDD. None included a formal discontinuation taper arm, because early Phase II data showed no withdrawal signal [4][8][9].

In BEGONIA (N=1,175), women receiving flibanserin 100 mg at bedtime reported a mean increase of 0.5 satisfying sexual events (SSEs) per month over placebo at 24 weeks (P<0.05) [4]. After stopping treatment, efficacy outcomes returned toward baseline by week 28 in the open-label extension cohort. No discontinuation-emergent adverse events exceeded the placebo-period incidence rate.

The DAISY trial (N=1,188) and VIOLET trial (N=1,185) produced similar findings: flibanserin modestly improved desire scores on the Female Sexual Function Index (FSFI) desire domain, with a mean drug-placebo difference of approximately 0.3 to 0.4 points on the 6-point scale [8][9]. Both trials reported that adverse events on drug (somnolence at 21.2%, dizziness at 11.4%, nausea at 10.4%) resolved within days of stopping [1][4].

An integrated safety analysis pooling data from five flibanserin trials (N=5,000+) found that the most common adverse events during treatment resolved with a median time to resolution of 3 to 5 days after discontinuation [3]. No new symptoms emerged after stopping in any treatment arm.

When Your Prescriber May Recommend Continuing

Not every patient should stop. The FDA label notes that if a woman has responded to flibanserin and tolerates it well, ongoing treatment may be warranted because HSDD is often a chronic condition [1]. The 2016 International Society for the Study of Women's Sexual Health (ISSWSH) process of care algorithm recommends reassessing treatment goals at 6-month intervals, not defaulting to automatic discontinuation [6].

Dr. Irwin Goldstein, director of San Diego Sexual Medicine, has noted: "HSDD has a neurobiological basis, and for some women, sustained pharmacotherapy is the most appropriate management, just as we would not reflexively stop an antidepressant in a patient with recurrent major depression" [10]. That clinical parallel is useful. The decision to stop should weigh symptom severity, relationship context, side-effect burden, and patient preference.

Factors that favor continued treatment include persistent HSDD symptoms before drug initiation, absence of bothersome side effects, and meaningful improvement in desire or distress scores on validated instruments like the FSFI or Female Sexual Distress Scale-Revised (FSDS-R) [6].

Restarting Flibanserin After a Break

If a woman stops and later decides to resume, the same titration approach applies. Begin with 100 mg at bedtime nightly (there is only one approved dose) and allow four to eight weeks for full effect [1]. The alcohol-interaction precautions and REMS requirements re-engage immediately upon restarting [7].

No published data address whether prior responders are more or less likely to respond a second time. Anecdotal clinical experience suggests that women who had a clear benefit on the first course tend to respond again, but this has not been confirmed in a controlled trial. The absence of receptor tolerance or tachyphylaxis data is a gap in the literature.

One practical note: flibanserin prescriptions require dispensing through a certified pharmacy under the REMS program. If a patient's previous pharmacy certification has lapsed or if she has switched pharmacies, re-enrollment may be needed before the first refill [7].

Common Concerns About Stopping Addyi

"Will I feel worse than before I started?" No clinical evidence supports rebound worsening of desire below pre-treatment baseline. The return of HSDD symptoms reflects the natural course of the condition, not a drug-withdrawal effect [3][4].

"Will my blood pressure drop dangerously?" Hypotension risk is present during active treatment, especially with concurrent alcohol or strong CYP3A4 inhibitors like fluconazole or ketoconazole [1]. After stopping, blood pressure normalizes within 24 to 48 hours as the drug clears. Women taking antihypertensives should confirm with their prescriber that no dose adjustments were made specifically to accommodate flibanserin.

"Should I switch to another medication instead of stopping?" Bremelanotide (Vyleesi), an on-demand melanocortin receptor agonist approved in 2019, is the only other FDA-approved pharmacologic option for premenopausal HSDD [11]. The two drugs have different mechanisms and dosing schedules (nightly oral vs. on-demand subcutaneous injection). Transitioning between them does not require a washout period, though a prescriber visit is needed for a new prescription and injection training.

"Can I stop if I'm also on an SSRI?" Many women with HSDD are also taking SSRIs, which can independently suppress desire. Stopping flibanserin does not require any change to the SSRI regimen. If desire worsens after flibanserin discontinuation and the SSRI is suspected as a contributor, that is a separate clinical conversation about SSRI-induced sexual dysfunction, not a flibanserin withdrawal issue [6].

Monitoring Checklist After Discontinuation

A structured self-monitoring plan improves the quality of the follow-up conversation with your prescriber:

• Days 1 to 3: Note whether somnolence, dizziness, or nausea resolve. These are the three most common on-treatment adverse events and typically clear first [1].
• Days 3 to 7: Observe sleep quality. Some women report mildly lighter sleep initially, likely because the sedating effect of the drug is absent. This is not insomnia caused by withdrawal.
• Weeks 1 to 2: Track desire using a simple daily 0-to-10 self-rating or the FSFI desire domain questions. Compare to your recollection of pre-treatment baseline.
• Week 4: Full reassessment with prescriber. Bring your tracking data. Discuss whether to resume, switch to bremelanotide, or pursue non-pharmacologic options such as cognitive-behavioral therapy for HSDD [6][12].

Flibanserin's steady-state volume of distribution is approximately 36,400 L, reflecting extensive tissue distribution, but clinical effects still dissipate within days of the last dose because receptor occupancy, not tissue stores, drives the pharmacologic effect [1][2].